



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Pending

Common Name: Degarelix

PDL Category: Antineoplastics-LHRH Analogs

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Lupron®	Recommended
Zoladex®	Recommended

Summary

Indications and Usage: Treatment of patients with advanced prostate cancer.¹

Mechanism of Action: Reversibly binds to pituitary GnRH receptors, reducing the release of gonadotropins and consequently testosterone.¹

Dosage Forms: Injection: 80mg and 120mg

Recommended Dosage: Starting dose is 240 mg given as two injections of 120 mg each, followed by maintenance doses of 80 mg administered as a single injection every 28 days.¹

Common Adverse Drug Reactions: Injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, increased weight, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT).¹

Contraindications: Patients with previous hypersensitivity reactions to degarelix.¹

Manufacturer: Ferring Pharmaceuticals, Inc.

Analysis: Degarelix is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Degarelix's mechanism of action allows a significantly faster reduction of testosterone levels when compared to Lupron®. In Phase III trials, Degarelix was found to be at least as effective as Lupron® in maintaining castrate levels of testosterone. It is recommended that Degarelix be added to the Preferred Drug List as a recommended drug.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input checked="" type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Degarelix [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; 2008.